article thumbnail

Lessons from Monte Carlo Models: Why Drug Development is Hard

DrugBaron

And today it has earned its place in the lexicon of life science venture capital, playing a key role in generating returns of investment houses across the globe. So what does the game look like to a late-stage investor or a pharma company head of R&D thinking about portfolio prioritisation? But it is not universal.

article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Smith identifies three key obstacles preventing broader acceptance of AI: Communication gaps : Pharmaceutical and computational science communities often struggle to understand each others technical languages, making collaboration difficult.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ACTO EXPANDS INVESTMENT IN ARTIFICIAL INTELLIGENCE TO SOLVE UNMET NEEDS IN THE LIFE SCIENCES INDUSTRY

ACTO

The life sciences industry is actively looking for new ways to leverage AI to bring drugs to market faster to patients waiting in need,” said Parth Khanna, CEO of ACTO. We see ACTO as a category leader with their powerful AI-first platform, which empowers pharma companies to consistently turn their field reps into top performers.

Science 52
article thumbnail

What to Expect at This Year’s Asembia Specialty Pharmacy Summit (Guest Post)

Drug Channels

Jayne discusses changes in the life science and specialty pharmacy industries since the COVID-19 pandemic began. She highlights three key trends that pharma companies, plan sponsors, and others will consider as we head to the upcoming Asembia Specialty Pharmacy Summit (October 26 to 29 in Las Vegas).

article thumbnail

Women in STEM with Kristina Torfgard

Drug Target Review

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company. Kristina is a pharmacist and holds a PhD in Medical Science from Linköping University.

article thumbnail

Claims that AI will “revolutionise pharma R&D” are (almost entirely) hype

DrugBaron

Billions of dollars have been invested in companies promising to “revolutionise pharma R&D” through the application of artificial intelligence – but it is now clear that global pharma companies, and not just tech bro’s, are buying into the claims. And there is no doubt that there is plenty of room for improvement.

article thumbnail

Compliant Science: The Critical Role of Compliance for Medical Affairs

H1 Blog

government has also implemented additional anti-bribery and anti-corruption laws that apply to life sciences companies doing business abroad. Non-compliance with these laws not only attracts hefty fines but can also severely damage the reputation of life sciences companies and harm public trust in their products and services.